Skip to content
Screener

Bioventus BVS U.S. — Total Net Sales

Similar metrics at other companies

Zebra Technologies logo
ZBRAU.S. — Total Net Sales
$660.75M+8.7%
Pilgrim's Pride Corporation logo
PPCU.S. — Total Net Sales
$2.64B-3.9%
Wabtec logo
WABAustralia / New Zealand — Total Net Sales
$113.25M-5.8%
Semtech logo
SMTCEurope — Total Net Sales
$30.13M-7.4%
Wabtec logo
WABAfrica — Total Net Sales
$81.5M+68.0%
Wabtec logo
WABEurope — Total Net Sales
$489M+7.8%

Other financials

Income statement

See full
Revenue$153.2M+3.8%
Gross profit$105.7M+3.5%
Operating income$19.1M+4.1%
Net income$33.4M+348%
EPS (diluted)$0.47+327%

Balance sheet

See full
Cash & equivalents$29.5M-10.5%
Total debt$263.7M-26.9%
Total equity$228.3M+41.6%
Total assets$673.3M-4.7%

Cash flow

See full
Operating cash flow$19.9M-23.4%
CapEx$960.0K+40.6%
Free cash flow$18.9M-25.1%

Valuation

See full
Market cap$1.19B+156%
Enterprise value$1.42B+79.7%
P/E21.8×
P/S+1.2×

Profitability

See full
Gross margin68.7%+1.1pp
Operating margin10%
Net margin9.4%+9.2pp
FCF margin16.2%+10.2pp

Returns & leverage

See full
Return on equity28%+27.5pp
Debt / equity1.2×-1.1×
Current ratio1.7×+0.2×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Bioventus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:43 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001665988-26-000042
Line itemThree Months Ended / June 27, 2026Three Months Ended / June 28, 2025Six Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Net sales$153,208$147,660$285,297$271,536
Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively)47,54245,57088,86286,390
Gross profit105,666102,090196,435185,146
Selling, general and administrative expense82,74079,110161,065152,612
Research and development expense3,1733,1725,6406,183
Restructuring costs(415)39
Depreciation and amortization1,0411,4392,1483,032
Loss on disposals182

Item 1. Financial Statements (Unaudited)

FAQ

What is Bioventus's U.S. — total net sales?
Bioventus (BVS) reported U.S. — total net sales of $134.47M in Q2 2026.
How has Bioventus's U.S. — total net sales changed year-over-year?
Bioventus's U.S. — total net sales increased by 4.4% year-over-year, from $128.78M to $134.47M.
What is the long-term trend for Bioventus's U.S. — total net sales?
Over 4 years (2021 to 2025), Bioventus's U.S. — total net sales has grown at a 6.7% compound annual growth rate (CAGR), from $387.55M to $502.1M.
What does U.S. — total net sales mean?
Represents the total revenue generated from the sale of medical products and services within the U.S. geographic segment, net of returns, allowances, and discounts. This is the primary measure of market demand and commercial success for the company's domestic operations. It serves as a fundamental indicator of top-line growth and market penetration.

Ask your AI about Bioventus's u.s. — total net sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude